semaglutide news november 28 2025 Are you eligible? Medicare's new GLP-1 Bridge program will cover certain weight-loss drugs starting this week. But as of now, the program isn't permanent: http://www.11alive.com/article/news/nation-world/medicare-covering-glp-1-weight-loss-drugs-bridge Generic versions of weight-loss drugs

Using patient reported outcomes in diabetes research and practice: recommendations from a national workshop

Clinical data shows semaglutide achieves HbA1c reductions of up to 1.7%2.0%, with weight loss exceeding 10% body mass in nearly 45%61% of patients, significantly outperforming earlier therapies

And on the whole it's failed - more than half the planet is projected to be overweight or obese by 2035, driving up cases of type 2 diabetes, heart disease and some cancers

For a patient with FFM of 45 kg, this means 6390 g protein daily distributed across 34 meals for optimal muscle protein synthesis

Semaglutide belongs to a class of drugs known as glucagon-like peptide-1 (GLP-1) receptor agonists

Once daily injectable liraglutide (marketed as Victoza for T2DM and Saxenda for obesity) and once weekly injectable semaglutide (marketed as Ozempic for T2DM and Wegovy for obesity) are two additional GLP-1 analogues, sharing 97% and 94% amino acid homology to GLP-1, respectively [ Figure 2 , Table 1 ]